Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galvus Review Delayed For Safety Analysis Of Primate Skin Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.
Advertisement

Related Content

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Merck Builds On Januvia Momentum With Two Supplementary Claims
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin
Novartis To Launch Exforge In September 2007
Bristol-Myers Squibb Latest To License DPP-4 Patents From OSI
Merck Janumet Study Demonstrates Glucose Reductions In Two Measures
Merck’s Januvia/Metformin Combo To Be Branded Janumet
Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia
Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia

Topics

Advertisement
UsernamePublicRestriction

Register

PS063360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel